Table of Contents Author Guidelines Submit a Manuscript
Journal of Ophthalmology
Volume 2018, Article ID 4565216, 6 pages
https://doi.org/10.1155/2018/4565216
Clinical Study

Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

1Department of Ophthalmology, Changhua Christian Hospital, Changhua, Taiwan
2School of Medicine, Chung Shan Medical University, Taichung, Taiwan
3Department of Optometry, DaYeh University, Changhua, Taiwan
4School of Medicine, National Taiwan University, Taipei, Taiwan

Correspondence should be addressed to San-Ni Chen; wt.gro.hcc@265801

Received 7 November 2017; Accepted 14 January 2018; Published 11 March 2018

Academic Editor: Toshihide Kurihara

Copyright © 2018 Yen-Chih Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. V. Good and Early treatment for retinopathy of prematurity cooperative group, “Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial,” Transactions of the American Ophthalmological Society, vol. 102, pp. 233–248, 2004. View at Google Scholar
  2. R. Axer-Siegel, I. Maharshak, M. Snir et al., “Diode laser treatment of retinopathy of prematurity: anatomical and refractive outcomes,” Retina, vol. 28, no. 6, pp. 839–846, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Dhawan, M. Dogra, A. Vinekar, A. Gupta, and S. Dutta, “Structural sequelae and refractive outcome after successful laser treatment for threshold retinopathy of prematurity,” Journal of Pediatric Ophthalmology and Strabismus, vol. 45, no. 6, pp. 356–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Sahni, N. V. Subhedar, and D. Clark, “Treated threshold stage 3 versus spontaneously regressed subthreshold stage 3 retinopathy of prematurity: a study of motility, refractive, and anatomical outcomes at 6 months and 36 months,” The British Journal of Ophthalmology, vol. 89, no. 2, pp. 154–159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. H. A. Mintz-Hittner, K. A. Kennedy, A. Z. Chuang, and BEAT-ROP Cooperative Group, “Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity,” The New England Journal of Medicine, vol. 364, no. 7, pp. 603–615, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. W. C. Wu, P. T. Yeh, S. N. Chen, C. M. Yang, C. C. Lai, and H. K. Kuo, “Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan,” Ophthalmology, vol. 118, no. 1, pp. 176–183, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. W. C. Wu, H. K. Kuo, P. T. Yeh, C. M. Yang, C. C. Lai, and S. N. Chen, “An updated study of the use of bevacizumab in the treatment of patients with prethreshold retinopathy of prematurity in Taiwan,” American Journal of Ophthalmology, vol. 155, no. 1, pp. 150–158.e1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. B. C. Harder, F. C. Schlichtenbrede, S. von Baltz, W. Jendritza, B. Jendritza, and J. B. Jonas, “Intravitreal bevacizumab for retinopathy of prematurity: refractive error results,” American Journal of Ophthalmology, vol. 155, no. 6, pp. 1119–1124.e1, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. C. K. Hwang, G. B. Hubbard, A. K. Hutchinson, and S. R. Lambert, “Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: a 5-year retrospective analysis,” Ophthalmology, vol. 122, no. 5, pp. 1008–1015, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Zhang, M. Yang, J. Zeng et al., “Comparison of intravitreal injection of ranibizumab versus laser therapy for zone II treatment-requiring retinopathy of prematurity,” Retina, vol. 37, no. 4, pp. 710–717, 2017. View at Publisher · View at Google Scholar · View at Scopus
  11. W. C. Wu, C. P. Shih, R. Lien et al., “Serum vascular endothelial growth factor after bevacizumab or ranibizumab treatment for retinopathy of prematurity,” Retina, vol. 37, no. 4, pp. 694–701, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. J. J. T. Chan, C. P. S. Lam, M. K. M. Kwok et al., “Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy,” Scientific Reports, vol. 6, no. 1, article 27082, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Chuluunbat, R. V. Paul Chan, N.-K. Wang et al., “Nonresponse and recurrence of retinopathy of prematurity after intravitreal ranibizumab treatment,” Ophthalmic Surgery, Lasers and Imaging Retina, vol. 47, no. 12, pp. 1095–1105, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. M. K. Erol, D. T. Coban, E. S. Sari et al., “Comparison of intravitreal ranibizumab and bevacizumab treatment for retinopathy of prematurity,” Arquivos Brasileiros de Oftalmologia, vol. 78, no. 6, pp. 340–343, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. S. N. Chen, I. Lian, Y. C. Hwang et al., “Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between ranibizumab and bevacizumab,” Retina, vol. 35, no. 4, pp. 667–674, 2015. View at Publisher · View at Google Scholar · View at Scopus
  16. T. C. Chen, T. H. Tsai, Y. F. Shih et al., “Long-term evaluation of refractive status and optical components in eyes of children born prematurely,” Investigative Ophthalmology & Visual Science, vol. 51, no. 12, p. 6140, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. W. C. Wu, R. I. Lin, C. P. Shih et al., “Visual acuity, optical components, and macular abnormalities in patients with a history of retinopathy of prematurity,” Ophthalmology, vol. 119, no. 9, pp. 1907–1916, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. E. L. Smith III, “Prentice Award Lecture 2010: a case for peripheral optical treatment strategies for myopia,” Optometry and Vision Science, vol. 88, no. 9, pp. 1029–1044, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. G. S. Robinson, M. Ju, S. C. Shih et al., “Nonvascular role for VEGF: VEGFR-1, 2 activity is critical for neural retinal development,” The FASEB Journal, vol. 15, no. 7, pp. 1215–1217, 2001. View at Publisher · View at Google Scholar
  20. J. Wang, X. Ren, L. Shen, S. E. Yanni, J. N. Leffler, and E. E. Birch, “Development of refractive error in individual children with regressed retinopathy of prematurity,” Investigative Opthalmology & Visual Science, vol. 54, no. 9, pp. 6018–6024, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. S. Yang, A. G. Wang, Y. F. Shih, and W. M. Hsu, “Long-term biometric optic components of diode laser-treated threshold retinopathy of prematurity at 9 years of age,” Acta Ophthalmologica, vol. 91, no. 4, pp. e276–e282, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. B. P. Connolly, E. Y. J. Ng, J. Arch McNamara, C. D. Regillo, J. F. Vander, and W. Tasman, “A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years,” Ophthalmology, vol. 109, no. 5, pp. 936–941, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. A. R. Fielder and G. E. Quinn, “Myopia of prematurity: nature, nurture, or disease?” The British Journal of Ophthalmology, vol. 81, no. 1, pp. 2-3, 1997. View at Publisher · View at Google Scholar · View at Scopus